Cargando…

Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age

BACKGROUND: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have stu...

Descripción completa

Detalles Bibliográficos
Autores principales: Takada, Koji, Kashiwagi, Shinichiro, Asano, Yuka, Goto, Wataru, Morisaki, Tamami, Shibutani, Masatsune, Tanaka, Hiroaki, Hirakawa, Kosei, Ohira, Masaichi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851811/
https://www.ncbi.nlm.nih.gov/pubmed/35177074
http://dx.doi.org/10.1186/s12957-022-02513-5
_version_ 1784652901724979200
author Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
author_facet Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
author_sort Takada, Koji
collection PubMed
description BACKGROUND: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have studied the relationship between age and TILs. Aging reduces host immunity, and we predict that it may also affect TILs. Thus, we hypothesized that older breast cancer (BC) patients may have low TIL density than younger BC patients. Here, we retrospectively analyzed the differences in TILs by age and the therapeutic effects of preoperative chemotherapy (POC) in BC patients who were aged either less than 45 years or more than 60 years. METHODS: We retrospectively examined the data of 356 breast cancer patients who underwent POC, including 75 patients aged ≤ 45 years and 116 patients aged > 60 years. Using pre-treatment needle biopsy specimens, TIL density was compared for each age group by Student’s t-test. After analyzing different factors that affect TIL density, prognostic factors were also examined. RESULTS: Older patients with triple-negative BC had significantly lower TIL density than younger patients, while in human epidermal growth factor receptor 2 (HER2)-enriched BC, TIL density was significantly higher in the younger age group than that in the older age group. In addition, younger patients with HER2-rich breast cancer showed significantly higher complete pathological response rates than older patients with HER2-rich BC. In addition, significant differences in overall survival were observed among these patients with triple-negative BC. CONCLUSIONS: Our study suggests that younger BC patients possess significantly higher TIL density than older patients. These differences may influence the therapeutic efficacy in highly immunogenic subtypes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02513-5.
format Online
Article
Text
id pubmed-8851811
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-88518112022-02-22 Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age Takada, Koji Kashiwagi, Shinichiro Asano, Yuka Goto, Wataru Morisaki, Tamami Shibutani, Masatsune Tanaka, Hiroaki Hirakawa, Kosei Ohira, Masaichi World J Surg Oncol Research BACKGROUND: Lymphocytes that surround cancer participate in tumor-related immune responses and are called tumor-infiltrating lymphocytes (TILs). Several recent reports suggest TILs index the tumor microenvironment and predict the therapeutic effect of chemotherapy. However, only few studies have studied the relationship between age and TILs. Aging reduces host immunity, and we predict that it may also affect TILs. Thus, we hypothesized that older breast cancer (BC) patients may have low TIL density than younger BC patients. Here, we retrospectively analyzed the differences in TILs by age and the therapeutic effects of preoperative chemotherapy (POC) in BC patients who were aged either less than 45 years or more than 60 years. METHODS: We retrospectively examined the data of 356 breast cancer patients who underwent POC, including 75 patients aged ≤ 45 years and 116 patients aged > 60 years. Using pre-treatment needle biopsy specimens, TIL density was compared for each age group by Student’s t-test. After analyzing different factors that affect TIL density, prognostic factors were also examined. RESULTS: Older patients with triple-negative BC had significantly lower TIL density than younger patients, while in human epidermal growth factor receptor 2 (HER2)-enriched BC, TIL density was significantly higher in the younger age group than that in the older age group. In addition, younger patients with HER2-rich breast cancer showed significantly higher complete pathological response rates than older patients with HER2-rich BC. In addition, significant differences in overall survival were observed among these patients with triple-negative BC. CONCLUSIONS: Our study suggests that younger BC patients possess significantly higher TIL density than older patients. These differences may influence the therapeutic efficacy in highly immunogenic subtypes. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12957-022-02513-5. BioMed Central 2022-02-17 /pmc/articles/PMC8851811/ /pubmed/35177074 http://dx.doi.org/10.1186/s12957-022-02513-5 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Takada, Koji
Kashiwagi, Shinichiro
Asano, Yuka
Goto, Wataru
Morisaki, Tamami
Shibutani, Masatsune
Tanaka, Hiroaki
Hirakawa, Kosei
Ohira, Masaichi
Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title_full Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title_fullStr Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title_full_unstemmed Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title_short Differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
title_sort differences in tumor-infiltrating lymphocyte density and prognostic factors for breast cancer by patient age
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851811/
https://www.ncbi.nlm.nih.gov/pubmed/35177074
http://dx.doi.org/10.1186/s12957-022-02513-5
work_keys_str_mv AT takadakoji differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT kashiwagishinichiro differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT asanoyuka differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT gotowataru differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT morisakitamami differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT shibutanimasatsune differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT tanakahiroaki differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT hirakawakosei differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage
AT ohiramasaichi differencesintumorinfiltratinglymphocytedensityandprognosticfactorsforbreastcancerbypatientage